Compare · MRK vs XENE
MRK vs XENE
Side-by-side comparison of Merck & Company Inc. (MRK) and Xenon Pharmaceuticals Inc. (XENE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and XENE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $295.19B, about 59.6x XENE ($4.95B).
- Over the past year, MRK is up 50.1% and XENE is up 63.9% - XENE leads by 13.8 points.
- MRK has been more active in the news (27 items in the past 4 weeks vs 23 for XENE).
- MRK has more recent analyst coverage (25 ratings vs 19 for XENE).
- Company
- Merck & Company Inc.
- Xenon Pharmaceuticals Inc.
- Price
- $119.01-0.40%
- $51.52+0.61%
- Market cap
- $295.19B
- $4.95B
- 1M return
- +6.90%
- -8.60%
- 1Y return
- +50.12%
- +63.95%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 27
- 23
- Recent ratings
- 25
- 19
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Latest MRK
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
Latest XENE
- Director Patou Gary sold $70,251 worth of shares (1,322 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 24,896 units (SEC Form 4) to cover withholding tax
- Director Cannon Gillian sold $63,237 worth of shares (1,190 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 45% to 1,455 units (SEC Form 4) to satisfy tax liability
- SEC Form 144 filed by Xenon Pharmaceuticals Inc.
- Director Patou Gary converted options into 2,645 shares, increasing direct ownership by 11% to 26,218 units (SEC Form 4)
- Director Machado Patrick converted options into 2,645 shares (SEC Form 4)
- Director Gover Justin D. converted options into 2,645 shares (SEC Form 4)
- Director Garofalo Elizabeth A. converted options into 2,645 shares (SEC Form 4)
- Director Gannon Steven converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 12% to 11,870 units (SEC Form 4) to cover withholding tax
- Director Cannon Gillian converted options into 2,645 shares (SEC Form 4)
- Director Svoronos Dawn converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 5% to 26,229 units (SEC Form 4) to satisfy withholding tax